Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 266,903
  • Shares Outstanding, K 84,463
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,960 K
  • EBIT $ -201 M
  • EBITDA $ -216 M
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58

Options Overview Details

View History
  • Implied Volatility 118.98% ( +17.77%)
  • Historical Volatility 44.34%
  • IV Percentile 64%
  • IV Rank 22.49%
  • IV High 491.83% on 10/22/24
  • IV Low 10.80% on 08/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 1,500
  • Open Int (30-Day) 1,571

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 3
  • High Estimate -0.30
  • Low Estimate -0.38
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +25.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.10 +4.56%
on 11/20/24
3.62 -10.61%
on 11/06/24
-0.35 (-9.86%)
since 10/21/24
3-Month
3.10 +4.56%
on 11/20/24
4.14 -21.93%
on 09/17/24
-0.58 (-15.29%)
since 08/21/24
52-Week
2.77 +17.03%
on 11/22/23
4.60 -29.65%
on 02/29/24
+0.37 (+12.75%)
since 11/21/23

Most Recent Stories

More News
Atea Pharmaceuticals Presents Promising Phase 2 Data on Bemnifosbuvir and Ruzasvir Combination for Hepatitis C at The Liver Meeting 2024

Atea Pharmaceuticals presents Phase 2 data on bemnifosbuvir and ruzasvir as potential hepatitis C treatments at AASLD 2024.Quiver AI SummaryAtea Pharmaceuticals, Inc. has presented three poster presentations...

AVIR : 3.23 (+2.22%)
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

AVIR : 3.23 (+2.22%)
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

AVIR : 3.23 (+2.22%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.50 (-0.94%)
AVIR : 3.23 (+2.22%)
CRSP : 46.35 (-1.93%)
APLS : 27.21 (-1.02%)
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...

BEAM : 23.83 (-2.69%)
FOLD : 9.50 (-0.94%)
AVIR : 3.23 (+2.22%)
CRSP : 46.35 (-1.93%)
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

AVIR : 3.23 (+2.22%)
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

AVIR : 3.23 (+2.22%)
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings

TransMedics Group TMDX is scheduled to report third-quarter 2024 results on Oct. 28, after market close.In the last reported quarter, the company’s adjusted earnings per share of 35 cents surpassed the...

AVIR : 3.23 (+2.22%)
MASI : 168.18 (+1.96%)
TMDX : 79.69 (+3.23%)
RDNT : 81.89 (-0.33%)
HSIC Gears Up for Q3 Earnings: Here's What You Need to Know

Henry Schein, Inc. HSIC is scheduled to release third-quarter 2024 results on Nov. 5, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.23,...

AVIR : 3.23 (+2.22%)
HSIC : 72.40 (-1.80%)
TMDX : 79.69 (+3.23%)
RDNT : 81.89 (-0.33%)
BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell.The company posted adjusted earnings per share (EPS) of $3.11 in the last reported...

AVIR : 3.23 (+2.22%)
BIO : 324.03 (+0.11%)
TMDX : 79.69 (+3.23%)
RDNT : 81.89 (-0.33%)

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 3.25
2nd Resistance Point 3.20
1st Resistance Point 3.18
Last Price 3.23
1st Support Level 3.12
2nd Support Level 3.07
3rd Support Level 3.05

See More

52-Week High 4.60
Fibonacci 61.8% 3.90
Fibonacci 50% 3.68
Fibonacci 38.2% 3.47
Last Price 3.23
52-Week Low 2.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar